Also known as BMS-986165 and Sotyktu.
Revenue +8.4% AER; core operating profit +11.2% AER; ORZEYFUL approved in US/Japan/China; MIMRYLO launched in US; zasocitinib accepted for FDA Priority Review; FY outlook raised for FX.
Once-daily oral TYK2 inhibitor showed statistical superiority to deucravacitinib for PASI100 and key secondary endpoints, with >35% achieving complete skin clearance at week 16.
